

CELL PANEL

TRIPLE NEGATIVE BREAST CANCER PANELS

ATCC has developed three Triple Negative Breast Cancer Panels based on how cell lines are classified into one of 6 subtypes. Triple Negative Breast Cancer Panel 1, Basal-like Morphology (ATCC® [TCP-1001™](#)) is composed of 10 triple negative breast tumor cell lines that share a basal-like morphology. Triple Negative Breast Cancer Panel 2, Mesenchymal & Luminal Morphology (ATCC® [TCP-1002™](#)) is composed of 6 triple negative breast tumor cell lines that share a mesenchymal-like morphology or LAR subtype. Triple Negative Breast Cancer Panel 3 (ATCC® [TCP-1003™](#)) contains all the items in ATCC® [TCP-1001™](#) and ATCC® [TCP-1002™](#) plus 2 triple negative breast cancer cell lines with an unclassified morphology.

ATCC® No.	Subtype ²	ATCC® No.	Name	Histology	Tumor Source	Mutant Gene	Zygoty	Gene Sequence	Protein Sequence	
Triple Negative Breast Cancer Panel 1 (ATCC® TCP-1001™)	Basal-Like Morphology	BL1	CRL-2340™	HCC2157	Primary ductal carcinoma	primary	KDM6A TP53	homozygous homozygous	c.1_4206del4206 c.742C>T	p.0? p.R248W
			CRL-2331™	HCC1599	Primary ductal carcinoma	primary	BRCA2 TP53	homozygous homozygous	c.4550_4559del10 c.673-2A>T	p.K1517fs*23 p.?
			CRL-2336™	HCC1937	Primary ductal carcinoma	primary	BRCA1 TP53	homozygous homozygous	c.5266_5267insC c.916C>T	p.Q1756fs*74 p.R306*
			CRL-2321™	HCC1143	Primary ductal carcinoma	primary	TP53	homozygous	c.743G>A	p.R248Q
			HTB-132™	MDA-MB-468	Adenocarcinoma	metastasis, pleural effusion	PTEN RB1 SMAD4 TP53	homozygous homozygous homozygous homozygous	c.253+1G>T c.265_2787del2523 c.1_1659del1659 c.818G>A	p.? p.? p.0? p.R273H
		CRL-2314™	HCC38	Primary ductal carcinoma	primary	CDKN2A TP53	homozygous homozygous	c.1_471del471 c.818G>T	p.0? p.R273L	
		BL2	CRL-2315™	HCC70	Primary ductal carcinoma	primary	PTEN TP53	homozygous homozygous	c.270delT c.743G>A	p.F90fs*9 p.R248Q
		IM	CRL-2335™	HCC1806	Primary acantholytic squamous cell carcinoma	primary	CDKN2A KDM6A STK11 TP53	homozygous homozygous homozygous homozygous	c.1_471del471 c.444_564del121 c.1109_1302del194 c.766_767insAA	p.0? p.0 p.? p.T256fs*90
			CRL-2322™	HCC1187	Primary ductal carcinoma	primary	TP53	homozygous	c.322_324delGGT	p.G108del
			HTB-123™	DU4475	Carcinoma	metastasis, skin	APC BRAF MAP2K4 RB1	homozygous heterozygous homozygous homozygous	c.4729G>T c.1799T>A c.1_1200del1200 c.1_2787del2787	p.E1577* p.V600E p.0? p.0?

ATCC® No.	Subtype ²	ATCC® No.	Name	Histology	Tumor Source	Mutant Gene	Zygoty	Gene Sequence	Protein Sequence
Triple Negative Breast Cancer Panel 2 (ATCC® TCP-1002™)	Mesenchymal-Like Morphology	M	<u>HTB-122™</u> BT-549	Ductal carcinoma	primary	PTEN RB1 TP53	homozygous homozygous homozygous	c.823delG c.265_607del343 c.747G>C	p.V275fs*1 p.? p.R249S
			<u>HTB-126™</u> Hs 578T	Carcinoma	primary	CDKN2A HRAS PIK3R1 TP53	homozygous heterozygous homozygous homozygous	c.1_471del471 c.35G>A c.1358_1359insTAA c.469G>T	p.0? p.G12D p.N453_454insN p.V157F
		MSL	<u>HTB-26™</u> MDA-MB-231	Adenocarcinoma	metastasis, pleural effusion	BRAF CDKN2A KRAS NF2 TP53	heterozygous homozygous heterozygous homozygous homozygous	c.1391G>T c.1_471del471 c.38G>A c.691G>T c.839G>A	p.G464V p.0? p.G13D p.E231* p.R280K
	LAR		<u>HTB-130™</u> MDA-MB-436	Adenocarcinoma	metastasis, pleural effusion	BRCA1 RB1	homozygous homozygous	c.5277+1G>A c.607_608ins227	p.? p.G203fs*9
			<u>HTB-24™</u> MDA-MB-157	Medullary carcinoma	metastasis, pleural effusion	NF1 TP53	homozygous homozygous	c.8253_8268del16 c.261_286delAGC-CCCCTCCTGGC-CCCTGTCATCTT	p.S2751fs*27 p.A88fs*52
		LAR	<u>HTB-131™</u> MDA-MB-453	Carcinoma	metastasis, pleural effusion	CDH1 PIK3CA	homozygous heterozygous	c.1913G>A c.3140A>G	p.W638* p.H1047R

ATCC® No.	Subtype ²	ATCC® No.	Name	Histology	Tumor Source	Mutant Gene	Zygoty	Gene Sequence	Protein Sequence
Contained in ATCC® TCP-1003™, described below.	Unclassified Morphology		<u>HTB-19™</u> BT-20	Carcinoma	primary	CDKN2A PIK3CA PIK3CA TP53	homozygous heterozygous heterozygous homozygous	c.1_471del471 c.1616C>G c.3140A>G c.394A>C	p.0? p.P539R p.H1047R p.K132Q
			<u>CRL-2324™</u> HCC1395	Primary ductal carcinoma	primary	BRCA1 CDKN2A PTEN TP53	homozygous homozygous homozygous homozygous	c.5251C>T c.1_471del471 c.635_1212del578 c.524G>A	p.R1751* p.0? p.N212fs*1 p.R175H

- 1 Described in J Clinical Inv (2011) 121(7):2750-2767.
- 2 These subtypes are classified as: (1) Basal-like, including subtypes BL1 (basal-like 1), BL2 (basal-like 2) and IM (immunomodulatory); (2) Mesenchymal-like, including subtypes M (mesenchymal) and MSL (mesenchymal stem-like); and, (3) LAR (luminal androgen receptor) with an LAR subtype.

The mutation data was obtained from the Sanger Institute Catalogue Of Somatic Mutations In Cancer web site, <http://www.sanger.ac.uk/cosmic> Bamford et al (2004) The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer, 91,355-358. ATCC and The Sanger Institute provide these data in good faith, but make no warranty, express or implied, nor assumes any legal liability or responsibility for any purpose for which the data are used.

10801 University Boulevard
Manassas, Virginia 20110-2209

703.365.2700

703.365.2701

sales@atcc.org

www.atcc.org

CB-122021-v02

©2022 American Type Culture Collection. The ATCC trademark and trade name, and any other trademarks listed in this publication are trademarks owned by the American Type Culture Collection unless indicated otherwise.

These products are for laboratory use only. Not for human or diagnostic use. ATCC products may not be resold, modified for resale, used to provide commercial services or to manufacture commercial products without prior ATCC written approval.